A study to assess if UDCA helps in liver regeneration in living donor liver transplant recipients as compared to a placebo

INTERVENTION: Intervention1: Ursodeoxycholic acid: Ursodeoxycholic acid 450mg twice a day Control Intervention1: Placebo: Placebo CONDITION: Health Condition 1: Z944‐ Liver transplant status PRIMARY OUTCOME: Regenerated liver volume ; Regeneration Liver Indices ; Percentage restoration of SLV (Standard liver volume) ; Regeneration index (%) : (Regenerated liver volume‐GW/GW)x100 ; Kinetic growth rate (volume in CC/Day) ; ; Timepoint: Post operative day 14 SECONDARY OUTCOME: Bile acid receptors expression for UDCA {FXR receptor concentration (hepatocytes), TGR‐5 receptor concentration (cholangiocytes) of the explant liver}Timepoint: POD 1 Daily ascitic fluid output in drain/24hrTimepoint: Daily till POD 14 Evaluation of monocyte number and function (flowcytometry)Timepoint: POD 1 Mitochondrial and nuclear DNA (markers of Ischemia‐reperfusion injury)‐ flowcytometryTimepoint: POD 14 Post‐operative complications in LDLT recipients ; Early Allograft dysfunction (EAD) as per Modified Olthoff criteriaTimepoint: POD 14 Serum levels of biomarkers (TNF alpha, IL 6, TGF Beta1, HGF)Timepoint: POD 0, 2, 5 and 7 T. Bilirubin, D. Bilirubin, AST, ALT, Serum Alkaline phosphatase, Gamma GT, PT/INRTimepoint: POD 1‐7, 10 and 14 Total ascitic fluid output till POD‐14Timepoint: POD 14 INCLUSION CRITERIA: Adult Living donor liver transplant recipients